Hyperfine (HYPR) announced the enrollment of 100 patients in its NEURO PMR study just 16 weeks after the study initiation, announced on April 15. The company said, “This milestone reflects strong clinician enthusiasm for accessible, point-of-care brain imaging and supports Hyperfine’s market expansion into outpatient neurology offices.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HYPR: